16.08.2018
Biofrontera AG DE0006046113
DGAP-News: Biofrontera AG: Biofrontera awarded contract with the U.S. Department of Veterans Affairs
DGAP-News: Biofrontera AG / Key word(s): Incoming Orders
Biofrontera AG: Biofrontera awarded contract with the U.S. Department of
Veterans Affairs
16.08.2018 / 10:59
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biofrontera awarded contract with the U.S. Department of Veterans Affairs
Leverkusen, Germany, August 16, 2018 - Biofrontera AG (NASDAQ: BFRA;
Frankfurt Stock Exchange: B8F), an international biopharmaceutical company,
today announced that its wholly owned US-subsidiary Biofrontera Inc. has
been awarded a 5-year contract with the U.S. Department of Veterans Affairs
(VA) for the sale of Ameluz(R) in combination with the medical device
BF-RhodoLED(R).
Ameluz(R) has been listed on the Federal Supply Schedule (FSS) since last
fall as announced in a news release on October 9, 2017. The contract is a
result of the FSS listing and covers the entire U.S. Federal Government.
"We are extremely pleased to be able to offer Ameluz(R) to all VA as well as
the U.S. Department of Defense medical facilities", says Prof. Dr. Hermann
Lübbert, CEO of Biofrontera AG. "The contract award validates the efficacy
of our product and allows more patients to receive treatment. We will
continue to pursue opportunities like this as part of our overall growth
strategy."
While the initial contract value of US $451,170 is based on certain sales
estimates, there is no limit on the volume of Ameluz(R) to be sold to each
facility. Under the contract, the price per tube of Ameluz(R) is
approximately 24.5% less than our reported price as it is subject to a
federal ceiling price, which is the highest price a supplier can charge to
the Government.
-END-
For enquiries, please contact: +49 (0) 214 87 63 2 0
Biofrontera AG [email protected]
Thomas Schaffer, Chief Financial Officer
IR UK: Seton Services +44 (0) 207 224 8468
Toni Vallen
IR and PR US: The Ruth Group +1 646-536-7035
IR: Tram Bui +1 508-280-6592
PR: Kirsten Thomas
About Biofrontera:
Biofrontera AG is an international biopharmaceutical company specializing in
the development and commercialization of a platform of pharmaceutical
products for the treatment of dermatological conditions and diseases caused
primarily by exposure to sunlight that results in sun damage to the skin.
Biofrontera's approved products focus on the treatment in the U.S. and
Europe of actinic keratoses, which are skin lesions that can sometimes lead
to skin cancer, as well as the treatment of certain forms of basal cell
carcinoma in the European Union. American Depositary Shares representing
Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under
the symbol "BFRA", and Biofrontera's ordinary shares are listed in the
Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also
available at www.biofrontera.com.
Forward Looking Statements:
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995 regarding
the public offering and the intended use of proceeds from the offering.
These statements may be identified by the use of forward-looking words such
as "anticipate," "believe," "forecast," "estimate" and "intend," among
others. Such forward-looking statements are based on the currently held
beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance, or
achievements of the Company, or industry results, to differ materially from
the results, financial condition, performance or achievements expressed or
implied by such forward-looking statements. These risks, uncertainties and
other factors are set forth in the Registration Statement on Form F-1 filed
with the SEC, including in the section "Risk Factors," and in future reports
filed with the SEC. Given these risks, uncertainties and other factors,
prospective investors are cautioned not to place undue reliance on these
forward-looking statements. The Company does not undertake an obligation to
update or revise any forward-looking statement.
---------------------------------------------------------------------------
16.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of News DGAP News Service
---------------------------------------------------------------------------
714815 16.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biofrontera AG ISIN: DE0006046113 können Sie bei EQS abrufen
Biotechnologie , 604611 , B8F , XETR:B8F